Victory Capital Management Inc. Invests $19.75 Million in Abcam plc (NASDAQ:ABCM)

Victory Capital Management Inc. acquired a new stake in Abcam plc (NASDAQ:ABCM – Get Rating) during the 4th quarter, HoldingsChannel reports. The firm acquired 1,269,247 shares of the company’s stock, valued at approximately $19,749,000.

Several other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Abcam by 48.7% in the first quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company’s stock valued at $56,000 after purchasing an additional 997 shares during the last quarter. Van ECK Associates Corp lifted its stake in Abcam by 41.4% in the fourth quarter. Van ECK Associates Corp now owns 3,536 shares of the company’s stock valued at $55,000 after purchasing an additional 1,035 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in Abcam in the first quarter valued at approximately $32,000. Advisors Capital Management LLC lifted its stake in Abcam by 3.8% in the third quarter. Advisors Capital Management LLC now owns 64,234 shares of the company’s stock valued at $1,078,000 after purchasing an additional 2,342 shares during the last quarter. Finally, Diversified Trust Co lifted its stake in Abcam by 17.2% in the fourth quarter. Diversified Trust Co now owns 17,050 shares of the company’s stock valued at $265,000 after purchasing an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 13.91% of the company’s stock.

Analysts Set New Price Targets

Separately, Royal Bank of Canada boosted their target price on shares of Abcam from $21.50 to $23.00 in a report on Friday, April 28th.

Abcam Price Performance

Shares of ABCM stock opened at $16.81 on Monday. Abcam plc has a 1 year low of $12.48 and a 1 year high of $18.38. The company’s fifty day simple moving average is $15.14 and its two-hundred day simple moving average is $15.40.

Abcam Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.